Endocrine Pharmacology Practice Questions

Q: Which drug is used for the treatment of bleeding gastrointestinal varices?

Terlipressin. **Explanation:** **Terlipressin** is the drug of choice for the management of acute bleeding esophageal varices. It is a synthetic analogue of Vasopressin (ADH) with a longer duration of action and a better safety profile. **Mechanism of Action:** Terlipressin acts primarily on **V1 receptors** located on vascular smooth muscle. Stimulation of these receptors causes potent **splanchnic vasoconstriction**. This reduces portal venous blood flow and lowers portal pressure, thereby allowing the variceal bleed to stop and facilitating endoscopic intervention. **Analysis of Incorrect Options:** * **A. Demeclocycline:** A tetracycline derivative that acts as an ADH antagonist at the V2 receptor. It is used in the treatment of SIADH, not for vasoconstriction. * **B. Desmopressin (dDAVP):** A selective **V2 receptor agonist**. It is used for Central Diabetes Insipidus, von Willebrand disease, and nocturnal enuresis. It lacks significant V1 activity and therefore does not cause the vasoconstriction required to treat varices. * **C. Leuprolide:** A GnRH agonist used in the treatment of prostate cancer, endometriosis, and precocious puberty. It has no effect on the vascular system or portal pressure. **High-Yield NEET-PG Pearls:** * **Drug of Choice:** Terlipressin is preferred over Vasopressin because it causes less systemic vasoconstriction (fewer cardiac side effects). * **Octreotide:** A somatostatin analogue often used as an alternative; it reduces portal pressure by inhibiting the release of vasodilator hormones like glucagon. * **Prophylaxis:** While Terlipressin treats *acute* bleeds, **Non-selective beta-blockers** (e.g., Propranolol, Nadolol) are used for the *primary prevention* of variceal bleeding.

Q: Estrogen replacement for postmenopausal symptoms causes an increase in:

Triglycerides. **Explanation:** The effect of Estrogen Replacement Therapy (ERT) on the lipid profile depends significantly on the route of administration. When estrogen is taken **orally**, it undergoes the "first-pass effect" in the liver. 1. **Why Triglycerides increase:** Oral estrogen stimulates the hepatic synthesis of triglycerides and increases the production of **VLDL (Very Low-Density Lipoprotein)** particles. Specifically, it enhances the expression of apolipoprotein C-III, which inhibits lipoprotein lipase, leading to an elevation in serum triglyceride levels. This is why oral ERT is often contraindicated in patients with severe hypertriglyceridemia (risk of pancreatitis). 2. **Why other options are incorrect:** * **LDL and Cholesterol:** Estrogen actually **decreases** LDL (the "bad" cholesterol) by increasing the expression of LDL receptors in the liver, leading to enhanced clearance. Consequently, total serum cholesterol levels typically decrease or remain stable. * **VLDL:** While VLDL production increases, the question specifically targets the primary lipid component measured in a standard profile that rises significantly—**Triglycerides**. In many clinical contexts, the rise in Triglycerides is the most clinically relevant adverse lipid change of oral ERT. **High-Yield Clinical Pearls for NEET-PG:** * **HDL:** Oral estrogen **increases HDL** (the "good" cholesterol), which is considered a cardioprotective effect. * **Route Matters:** **Transdermal estrogen** bypasses the liver, thus it has a neutral effect on triglycerides and is preferred in women with hypertriglyceridemia. * **Coagulation:** Oral estrogen increases clotting factors (II, VII, IX, X) and decreases Antithrombin III, increasing the risk of Venous Thromboembolism (VTE).

Q: Which of the following drugs decreases hepatic glucose output and improves peripheral insulin utilization?

Pioglitazone. **Explanation:** The correct answer is **Pioglitazone**. **Mechanism of Action:** Pioglitazone belongs to the **Thiazolidinedione (TZD)** class. It acts as a selective agonist for the nuclear receptor **PPAR-γ** (Peroxisome Proliferator-Activated Receptor-gamma). Activation of this receptor leads to the transcription of genes involved in glucose and lipid metabolism. Its primary effects are: 1. **Liver:** It decreases hepatic glucose output (gluconeogenesis). 2. **Peripheral Tissues (Muscle/Adipose):** It increases the expression of glucose transporters (GLUT-4), thereby improving peripheral insulin sensitivity and glucose utilization. **Analysis of Incorrect Options:** * **A & B (Chlorpropamide & Glyburide):** These are **Sulfonylureas**. Their primary mechanism is to stimulate insulin release from pancreatic beta cells by closing ATP-sensitive K+ channels. They do not directly improve peripheral insulin sensitivity. * **C (Miglitol):** This is an **Alpha-glucosidase inhibitor**. It acts locally in the intestine to delay the absorption of carbohydrates by inhibiting the enzyme that breaks down oligosaccharides into monosaccharides. It has no direct effect on hepatic glucose output or peripheral utilization. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects of TZDs:** Weight gain, **fluid retention/edema** (contraindicated in NYHA Class III/IV heart failure), and increased risk of bone fractures. * **Pioglitazone specific:** It has been associated with a potential risk of **bladder cancer** (avoid in patients with active or past history of bladder cancer). * **Metformin vs. TZDs:** While both are "insulin sensitizers," Metformin primarily acts on the liver (via AMPK activation), whereas TZDs have a more pronounced effect on peripheral adipose and muscle tissue.

Q: Which drug is NOT used in the treatment of Pituitary Adenoma?

Orlistat. **Explanation:** The correct answer is **Orlistat** because it is a **lipase inhibitor** used for the management of obesity. It works locally in the gastrointestinal tract to prevent the absorption of dietary fats and has no pharmacological role in modulating pituitary hormones or treating intracranial adenomas. **Analysis of Options:** * **Octreotide (Option A):** A long-acting **Somatostatin analogue**. It is the first-line medical therapy for **Acromegaly** (GH-secreting pituitary adenoma) and is also used in TSH-secreting tumors. It inhibits the release of Growth Hormone by binding to SSTR-2 and SSTR-5 receptors. * **Bromocriptine (Option B):** A **Dopamine (D2) agonist**. It is the drug of choice for **Prolactinomas**. Dopamine naturally inhibits prolactin release; thus, bromocriptine effectively reduces both prolactin levels and tumor size. * **Letrozole (Option D):** An **Aromatase inhibitor**. While primarily used in breast cancer, it is used off-label in the management of **Gonadotroph adenomas** and sometimes in macro-prolactinomas that are resistant to dopamine agonists, as it reduces the feedback effects of estrogen on the pituitary. **NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC) for Prolactinoma:** Cabergoline (preferred over Bromocriptine due to higher efficacy and better side-effect profile). * **DOC for Acromegaly:** Surgical resection (Trans-sphenoidal surgery). Octreotide is the medical DOC. * **Pegvisomant:** A Growth Hormone receptor antagonist used for refractory Acromegaly; it blocks the peripheral action of GH rather than inhibiting its secretion from the tumor. * **Pasireotide:** A newer somatostatin analogue with high affinity for SSTR-5, often used in **Cushing’s Disease** (ACTH-secreting adenoma).

Q: Which of the following corticosteroids has the least glucocorticoid action?

Ciclesonide. ### Explanation The correct answer is **Ciclesonide**. The question asks for the corticosteroid with the **least systemic glucocorticoid action**. This is determined by the drug’s potency and its delivery mechanism. **Why Ciclesonide is correct:** Ciclesonide is a **prodrug** used primarily as an inhaled corticosteroid (ICS) for asthma. It is activated by esterases specifically in the bronchial epithelium to its active metabolite, des-ciclesonide. It has **minimal systemic bioavailability** (<1%) and high plasma protein binding, which significantly limits systemic glucocorticoid side effects [1]. Among the options provided, it is designed to have negligible systemic glucocorticoid activity compared to systemic steroids. **Why the other options are incorrect:** * **Dexamethasone and Betamethasone:** These are **long-acting, high-potency systemic glucocorticoids**. They have maximal glucocorticoid activity with zero mineralocorticoid activity. They are used when powerful anti-inflammatory effects are required. * **Fludrocortisone:** While primarily known for its very high **mineralocorticoid** potency (used in Addison’s disease), it still possesses significant systemic glucocorticoid activity (about 10–15 times that of cortisol). Compared to a localized prodrug like Ciclesonide, its systemic glucocorticoid impact is much higher. **High-Yield Clinical Pearls for NEET-PG:** * **Potency Ratio:** Dexamethasone/Betamethasone are the most potent systemic glucocorticoids (Potency = 25–30; Dose = 0.75 mg). * **Ciclesonide Advantage:** Because it is activated only in the lungs, it carries a lower risk of **oropharyngeal candidiasis** compared to other inhaled steroids like Budesonide or Fluticasone. * **Mineralocorticoid Potency:** Fludrocortisone is the drug of choice for mineralocorticoid replacement. * **Short-acting steroid:** Hydrocortisone (equal glucocorticoid and mineralocorticoid action).

Q: Hyperglycemia is caused by all EXCEPT:

Indomethacin. **Explanation:** The correct answer is **Indomethacin**. Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis. Unlike the other options, it does not typically cause hyperglycemia; in fact, some studies suggest NSAIDs may slightly increase insulin sensitivity or have a neutral effect on blood glucose. **Why the other options are wrong (Causes of Hyperglycemia):** * **Steroids (Glucocorticoids):** These are potent hyperglycemic agents. They increase gluconeogenesis in the liver, decrease peripheral glucose uptake in muscles, and promote lipolysis, leading to "Steroid-induced Diabetes." * **Diuretics:** Specifically **Thiazides** and **Loop diuretics** cause hyperglycemia. They lead to hypokalemia, which inhibits the release of insulin from pancreatic beta cells (as insulin release is a potassium-dependent process). * **Beta-blockers:** Non-selective beta-blockers (like Propranolol) interfere with insulin release (mediated by $\beta_2$ receptors) and decrease peripheral glucose utilization. Crucially, they also mask the autonomic warning symptoms of hypoglycemia (tachycardia, tremors), making them risky for diabetics. **High-Yield Clinical Pearls for NEET-PG:** * **Drugs causing Hyperglycemia:** "S-T-A-N-D": **S**teroids, **T**hiazides, **A**typical antipsychotics (Clozapine/Olanzapine), **N**iacin, **D**iazoxide/Protease Inhibitors. * **Diazoxide:** A K+ channel opener that hyperpolarizes beta cells, inhibiting insulin release; used specifically to treat insulinomas. * **Beta-blocker Exception:** While they cause hyperglycemia, their most dangerous effect in diabetics is **masking hypoglycemia**, except for sweating (which is mediated by cholinergic fibers).

Q: Which of the following conditions is an indication for the use of somatostatin?

Bleeding esophageal varices. **Explanation:** **Somatostatin** is a potent inhibitory peptide produced by the hypothalamus and the delta cells of the pancreas. Its primary clinical utility in **Bleeding Esophageal Varices** (Option B) stems from its ability to cause **splanchnic vasoconstriction**. By reducing portal venous pressure and decreasing blood flow to the collateral variceal vessels, it helps control acute hemorrhage. While the synthetic analog **Octreotide** is more commonly used due to its longer half-life, somatostatin remains a classic pharmacological indication for this condition. **Analysis of Incorrect Options:** * **A. Zollinger-Ellison Syndrome (ZES):** While somatostatin inhibits gastrin, the first-line treatment for ZES is high-dose **Proton Pump Inhibitors (PPIs)** or surgical resection. Somatostatin analogs are rarely the primary choice. * **C. Steatorrhoea:** Somatostatin actually **causes** steatorrhoea as a side effect because it inhibits the secretion of pancreatic enzymes and reduces gallbladder contraction, leading to fat malabsorption. * **D. Macroprolactinoma:** The treatment of choice for prolactinomas is **Dopamine agonists** (e.g., Cabergoline, Bromocriptine). Somatostatin analogs are used for Growth Hormone-secreting tumors (Acromegaly), not prolactinomas. **High-Yield NEET-PG Pearls:** * **Mechanism:** Somatostatin inhibits "everything" (Growth hormone, TSH, Insulin, Glucagon, Gastrin, and Secretin). * **Octreotide vs. Somatostatin:** Octreotide is preferred clinically because it has a longer half-life (1.5 hours) compared to natural somatostatin (1–3 minutes). * **Other Indications:** Acromegaly, Carcinoid syndrome, VIPoma, and persistent diarrhea in AIDS patients. * **Side Effect:** Cholelithiasis (due to inhibition of CCK and gallbladder stasis).

Q: Apart from ovulation induction, clomiphene citrate can be tried for which of the following disorders?

Oligospermia. **Explanation:** **Clomiphene Citrate (CC)** is a Selective Estrogen Receptor Modulator (SERM). While primarily known for female ovulation induction, it is also used off-label in male infertility. **Why Oligospermia is correct:** In men, Clomiphene acts by blocking estrogen receptors at the level of the hypothalamus and pituitary gland. This inhibits the negative feedback loop of estrogen, leading to an increased secretion of **GnRH, FSH, and LH**. * **FSH** stimulates the Sertoli cells to support spermatogenesis. * **LH** stimulates Leydig cells to produce endogenous **testosterone**. This hormonal surge can improve sperm count and concentration in men with idiopathic oligospermia, provided they have a functional hypothalamic-pituitary-gonadal axis. **Why other options are incorrect:** * **B. Erectile Dysfunction:** This is primarily a vascular or neurological issue (treated with PDE5 inhibitors like Sildenafil), not a gonadotropin deficiency. * **C. Asherman’s Syndrome:** This involves intrauterine adhesions (structural defect). CC cannot restore the endometrium; treatment requires hysteroscopic adhesiolysis. * **D. Carcinoma Endometrium:** CC is actually **contraindicated** or used with extreme caution in estrogen-dependent tumors because its long-term use can potentially have a proliferative effect on the endometrium. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Competitive antagonist of estrogen receptors in the hypothalamus (increases GnRH pulse frequency). * **Side Effects:** Multiple pregnancies (mostly twins), hot flashes, and **ovarian hyperstimulation syndrome (OHSS)** (though less common than with gonadotropins). * **Dose for Ovulation:** Usually 50 mg/day for 5 days (Day 2 to Day 6 or Day 3 to Day 7 of the cycle). * **Anti-estrogenic effect:** It can cause thinning of the cervical mucus and endometrium, which may sometimes lead to a "conception-ovulation gap."

Q: Which antidiabetic drug is used for both Type 1 and Type 2 diabetes mellitus?

Pramlinitide. **Explanation:** **Pramlintide** is a synthetic analogue of **Amylin**, a hormone co-secreted with insulin from pancreatic beta cells. It works by slowing gastric emptying, suppressing postprandial glucagon secretion, and increasing satiety. Since its mechanism of action is independent of endogenous insulin production and instead focuses on modulating glucose appearance in the blood, it is the only non-insulin antidiabetic drug FDA-approved for use in **both Type 1 and Type 2 Diabetes Mellitus** (as an adjunct to mealtime insulin). **Why the other options are incorrect:** * **Sulphonylureas (e.g., Glipizide):** These are insulin secretagogues that require functional pancreatic beta cells to work. They are ineffective in Type 1 DM where beta cells are destroyed. * **Metformin:** A biguanide that primarily decreases hepatic glucose production. While sometimes used off-label in obese Type 1 patients to reduce insulin resistance, it is officially indicated only for Type 2 DM. * **Acarbose:** An alpha-glucosidase inhibitor that delays carbohydrate absorption. Like Metformin, it is primarily indicated for Type 2 DM and is not standard therapy for Type 1 DM. **High-Yield NEET-PG Pearls:** * **Route of Administration:** Pramlintide must be administered via **subcutaneous injection** before major meals. * **Major Side Effect:** Severe hypoglycemia (when used with insulin) and gastrointestinal upset (nausea). * **Contraindication:** It is contraindicated in patients with **gastroparesis** due to its effect on slowing gastric emptying. * **Weight Effect:** Unlike insulin or sulphonylureas, Pramlintide is associated with **weight loss**.

Question 1

Which drug is used for the treatment of bleeding gastrointestinal varices?

Accepted Answer

Terlipressin

Answer

Demeclocycline

Answer

Desmopressin

Answer

Leuprolide

Question 2

Estrogen replacement for postmenopausal symptoms causes an increase in:

Accepted Answer

Triglycerides

Answer

LDL

Answer

Cholesterol

Answer

VLDL

Question 3

Which of the following drugs decreases hepatic glucose output and improves peripheral insulin utilization?

Accepted Answer

Pioglitazone

Answer

Chlorpropamide

Answer

Glyburide

Answer

Miglitol

Question 4

Which drug is NOT used in the treatment of Pituitary Adenoma?

Accepted Answer

Orlistat

Answer

Octreotide

Answer

Bromocriptine

Answer

Letrozole

Question 5

Which of the following corticosteroids has the least glucocorticoid action?

Accepted Answer

Ciclesonide

Answer

Fludrocortisone

Answer

Dexamethasone

Answer

Betamethasone

Question 6

Hyperglycemia is caused by all EXCEPT:

Accepted Answer

Indomethacin

Answer

Beta blockers

Answer

Steroids

Answer

Diuretics

Question 7

Which of the following statements regarding carbimazole is NOT true when compared to propylthiouracil?

Accepted Answer

Carbimazole crosses the placenta less than propylthiouracil.

Answer

Carbimazole is more potent than propylthiouracil.

Answer

Carbimazole can be used as a single daily dose, whereas propylthiouracil needs to be given thrice daily.

Answer

Carbimazole does not inhibit the peripheral conversion of T4 to T3.

Question 8

Which of the following conditions is an indication for the use of somatostatin?

Accepted Answer

Bleeding esophageal varices

Answer

Zollinger Ellison syndrome

Answer

Steatorrhoea

Answer

Macroprolactinoma

Question 9

Apart from ovulation induction, clomiphene citrate can be tried for which of the following disorders?

Accepted Answer

Oligospermia

Answer

Erectile dysfunction

Answer

Asherman's syndrome

Answer

Carcinoma endometrium

Question 10

Which antidiabetic drug is used for both Type 1 and Type 2 diabetes mellitus?

Accepted Answer

Pramlinitide

Answer

Sulphonylureas

Answer

Metformin

Answer

Acarbose

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?